Liver disease kills approximately two million people per annum. Although organ transplant is a viable option to treat disease, many patients are not candidates for this type of treatment or die on the transplant waiting list.

Stimuliver is developing a disruptive liver implant to treat critically failing liver function in humans. 
The implant will be placed underneath the skin to ‘top up’ the patient’s reduced liver function. Lab engineered liver tissue will be produced from human stem cells, providing a scalable and renewable source of human liver tissue. The development of the liver implant to clinical grade will provide patients with a renewable treatment option for their disease.



Biotechnology

Health Care

Life Sciences

Medical Devices

Stimuliver

Stimuliver's headquarters in Copenhagen N, Denmark

Description

People (5)

Dagmara Szkolnicka

Giles Dudley

Joakim Nguyen Sørensen

Klaus Langhoff-Roos

Justyna Magdalena Kowal

Jobs